Heron Loses Bids to Block Azurity Copy of Cinvanti Nausea Drug

Heron Therapeutics Inc. lost two lawsuits over Azurity Pharmaceuticals Inc.'s proposed copy of nausea-prevention drug Cinvanti, as a federal judge’s invalidation of two patents in one case triggered a prior agreement that 10 other patents aren’t infringed.

Judge William C. Bryson issued the final judgments Monday in favor of Azurity in the US District Court for the District of Delaware. The two related suits targeted Azurity’s proposed follow-on version of Cinvanti’s aprepitant injectable emulsion that relies on Heron’s clinical data for US Food and Drug Administration approval.

Bryson invalidated US Patent Nos. 12,115,255 and 12,290,520 after a November bench trial, ...